LDA has been accepted as partner in the Environmental Protection Agency’s Pesticide Environmental Stewardship Program (PESP).The Pesticide Environmental Stewardship Program (PESP) is a voluntary program that forms partnerships to reduce the potential health and environmental risks associated with pests and pesticide use and to implement pollution prevention strategies. LDA has been accepted as partner in […]
Govt. Departments & Policies
The departments and agencies of the federal government often play a role in Lyme disease. They may issue policies, guidelines, advisories, or other information which may be useful to Lyme patients, doctors, or the general public. LDA may link to or list some of those government publications which it feels may be important. Complete agency or department information on Lyme disease may be found on each individual agency/department website.
Candy Brassard, Senior Biologist, U.S. Environmental Protection Agency Office of Pesticide Programs; C. Ben Beard, PhD, Director, Bacterial Diseases Branch, Division of Vector-Borne Infectious Diseases, Centers for Disease Control & Prevention at a Meeting at EPA on Lyme in Virginia in 2006.
Spring 2009, Dr. Betty Maloney, Minnesoto; Tim Lynagh, Legislative Director for Congressman Christopher Smith (NJ-4); and Pat Smith, President, Lyme Disease Association; in the office of Congressman Chris Smith (not pictured) after a meeting with NIH Lyme Disease Program officials on the problems with Lyme disease, a NIH Lyme research agenda, and how patients are […]
The first portion of this article first appeared in Tiny Tick Tales published by the Lyme Disease Association of New Jersey (LDANJ), now Lyme Disease Association. The second article appeared in the Lyme Times. Updates follow each piece. This entire article appeared in the Time for Lyme Newsletter. May 1999 THE LDANJ VISITS THE US […]
REMARKS OF PAT SMITH, PRESIDENT, LYME DISEASE ASSOCIATION, INC. BEFORE THE VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE, MAY 21, 2002. Why more adverse events were seen after the vaccine reached the market: People receiving Lymerix after product launch lived in Lyme-endemic areas. REMARKS OF PAT SMITH, PRESIDENT, LYME DISEASE ASSOCIATION, INC. BEFORE […]
SPECIAL REPORT: LDA MEETS WITH FDA ON LYMERIX On January 22, 2002 in Bethesda, MD., the LDA was able to get a private meeting with the FDA on the vaccine issue, despite reluctance by the FDA to grant the meeting. Congressman Chris Smith helped facilitate the setup of this meeting. Patricia Smith, President, Lyme […]
I am here today because we do favor a safe and effective vaccine, but we are unsure whether an OSP A based vaccine can meet those criteria. Since the inception of OSP A vaccine trials, we heard from individuals experiencing difficulties after immunization. The information was startling, not only because of the problems described, but […]
Assays for Antibodies to Borrelia burgdorferi; Limitations, Use, and Interpretation for Supporting a Clinical Diagnosis of Lyme Disease July 7, 1997 Purpose FDA is advising you about the potential for misdiagnosis of Lyme disease. The results of commonly marketed assays for detecting antibody to Borrelia burgdorferi (anti-Bb), the organism that causes Lyme disease, may be […]
THE LDANJ VISITS THE US ARMY CENTERS FOR HEALTH PROMOTION & PREVENTION, CHPPM by: Pat Smith, with input from Corey Lakin and USACHPPM In May 1999, Association Vice President Corey Lakin and I visited the US Army Centers for Health Promotion and Prevention, USACHPPM, at Aberdeen Proving Grounds, Maryland. USACHPPM is the preventive medicine arm […]